XML 49 R34.htm IDEA: XBRL DOCUMENT
v3.25.1

Revenue from Contract with Customer (Policies) | 6 Months Ended
--- | ---
Mar. 29, 2025
Revenue from Contract with Customer [Abstract] |
Revenue | (2) Revenue The Company accounts for revenue pursuant to ASC 606, Revenue from Contracts with Customers (ASC 606), and generates revenue from the sale of its products, primarily medical imaging systems and related components and software, diagnostic tests and assays and surgical disposable products, and related services, which are primarily support and maintenance services on its medical imaging systems, and to a lesser extent installation, training and repairs. In addition, the Company generates service revenue from performing laboratory testing services through its Biotheranostics CLIA laboratory, which is included in its Molecular Diagnostics business. The Company’s products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors and resellers. Revenue is recorded net of sales tax. The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis:
|  | Three Months Ended March 29, 2025 |  | Three Months Ended March 30, 2024
Business (in millions) | United States | International | Total |  | United States | International | Total
Diagnostics: |  |  |  |  |  |  |
| Cytology & Perinatal | $ | 71.1 |  | $ | 47.4 |  | $ | 118.5 |  |  | $ | 70.7 |  | $ | 49.8 |  | $ | 120.5 |
| Molecular Diagnostics | 258.7 |  | 67.3 |  | 326.0 |  |  | 255.4 |  | 67.3 |  | 322.7 |
| Blood Screening | 9.1 |  | — |  | 9.1 |  |  | 6.9 |  | — |  | 6.9 |
Total | $ | 338.9 |  | $ | 114.7 |  | $ | 453.6 |  |  | $ | 333.0 |  | $ | 117.1 |  | $ | 450.1 |
Breast Health: |  |  |  |  |  |  |
| Breast Imaging | $ | 209.4 |  | $ | 62.5 |  | $ | 271.9 |  |  | $ | 234.9 |  | $ | 71.8 |  | $ | 306.7 |
| Interventional Breast Solutions | 62.0 |  | 22.3 |  | 84.3 |  |  | 60.4 |  | 17.5 |  | 77.9 |
Total | $ | 271.4 |  | $ | 84.8 |  | $ | 356.2 |  |  | $ | 295.3 |  | $ | 89.3 |  | $ | 384.6 |
GYN Surgical | $ | 117.0 |  | $ | 45.5 |  | $ | 162.5 |  |  | $ | 115.6 |  | $ | 40.4 |  | $ | 156.0 |
Skeletal Health | $ | 17.6 |  | $ | 15.4 |  | $ | 33.0 |  |  | $ | 15.5 |  | $ | 11.6 |  | $ | 27.1 |
|  | $ | 744.9 |  | $ | 260.4 |  | $ | 1,005.3 |  |  | $ | 759.4 |  | $ | 258.4 |  | $ | 1,017.8 |
|  | Six Months Ended March 29, 2025 |  | Six Months Ended March 30, 2024
Business (in millions) | United States | International | Total |  | United States | International | Total
Diagnostics: |  |  |  |  |  |  |
| Cytology & Perinatal | $ | 147.1 |  | $ | 96.9 |  | $ | 244.0 |  |  | $ | 140.5 |  | $ | 100.0 |  | $ | 240.5 |
| Molecular Diagnostics | 521.2 |  | 145.7 |  | 666.9 |  |  | 502.9 |  | 139.6 |  | 642.5 |
| Blood Screening | 13.3 |  | — |  | 13.3 |  |  | 14.9 |  | — |  | 14.9 |
Total | $ | 681.6 |  | $ | 242.6 |  | $ | 924.2 |  |  | $ | 658.3 |  | $ | 239.6 |  | $ | 897.9 |
Breast Health: |  |  |  |  |  |  |
| Breast Imaging | $ | 425.1 |  | $ | 128.3 |  | $ | 553.4 |  |  | $ | 463.3 |  | $ | 144.8 |  | $ | 608.1 |
| Interventional Breast Solutions | 128.4 |  | 43.4 |  | 171.8 |  |  | 121.5 |  | 32.7 |  | 154.2 |
Total | $ | 553.5 |  | $ | 171.7 |  | $ | 725.2 |  |  | $ | 584.8 |  | $ | 177.5 |  | $ | 762.3 |
GYN Surgical | $ | 238.9 |  | $ | 90.0 |  | $ | 328.9 |  |  | $ | 240.8 |  | $ | 77.4 |  | $ | 318.2 |
Skeletal Health | $ | 28.8 |  | $ | 20.0 |  | $ | 48.8 |  |  | $ | 29.2 |  | $ | 23.3 |  | $ | 52.5 |
|  | $ | 1,502.8 |  | $ | 524.3 |  | $ | 2,027.1 |  |  | $ | 1,513.1 |  | $ | 517.8 |  | $ | 2,030.9 |
|  | Three Months Ended |  | Six Months Ended
Geographic Regions (in millions) |  | March 29, 2025 | March 30, 2024 |  | March 29, 2025 | March 30, 2024
United States |  | $ | 744.9 |  | $ | 759.4 |  |  | $ | 1,502.8 |  | $ | 1,513.1 |
Europe |  | 146.5 |  | 137.0 |  |  | 295.4 |  | 279.8 |
Asia-Pacific |  | 59.7 |  | 64.4 |  |  | 119.5 |  | 128.2 |
Rest of World |  | 54.2 |  | 57.0 |  |  | 109.4 |  | 109.8 |
|  | $ | 1,005.3 |  | $ | 1,017.8 |  |  | $ | 2,027.1 |  | $ | 2,030.9 |
The following table provides revenue recognized by source:
|  | Three Months Ended |  | Six Months Ended
Revenue by type (in millions) |  | March 29, 2025 | March 30, 2024 |  | March 29, 2025 | March 30, 2024
Disposables |  | $ | 636.9 |  | $ | 618.9 |  |  | $ | 1,300.6 |  | $ | 1,247.8 |
Capital equipment, components and software |  | 155.8 |  | 209.1 |  |  | 310.0 |  | 408.2 |
Service |  | 207.9 |  | 185.0 |  |  | 406.5 |  | 363.8 |
Other |  | 4.7 |  | 4.8 |  |  | 10.0 |  | 11.1 |
|  | $ | 1,005.3 |  | $ | 1,017.8 |  |  | $ | 2,027.1 |  | $ | 2,030.9 |
The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. Transfer of control for the Company’s products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains the use of and substantially all of the remaining benefits of the product. As such, the Company’s performance obligation related to product sales is satisfied at a point in time. Revenue from support and maintenance contracts, extended warranty, and professional services for installation, training and repairs is recognized over time based on the period contracted or as the services are performed as these methods represent a faithful depiction of the transfer of goods and services. The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction and is most often equal to the transaction price in the contract. Payment terms are typically 30 days in the U.S. but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within costs of product revenue when the corresponding revenue is recognized. The Company also places instruments (or equipment) at customer sites but retains title to the instrument. The customer has the right to use the instrument for a period of time, and the Company recovers the cost of providing the instrument through the sales of disposables, namely tests and assays in Diagnostics and handpieces in GYN Surgical. These types of agreements include an embedded lease, which is generally an operating lease, for the right to use an instrument and no instrument revenue is recognized at the time of instrument delivery. The Company recognizes a portion of the revenue allocated to the embedded lease concurrent with the sale of disposables over the term of the agreement. Revenue from laboratory testing services, which is generated by the Company’s Biotheranostics business, is recognized based upon contracted amounts with payors and historical cash collection experience for the same test or same payor group. Revenue is recognized once the laboratory services have been performed, the results have been delivered to the ordering physician, the payor has been identified, and insurance has been verified. The estimated timeframes for cash collection are three months for Medicare payors, six months for Medicare Advantage payors, and nine months for commercial payors. Generally, the contracts for capital equipment include multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price to each performance obligation using its best estimate of the standalone selling price of each distinct good or service in the contract. The Company determines its best estimate of standalone selling price using average selling prices over 3- to 12-month periods of data depending on the products or nature of the services coupled with current market considerations. If the product or service does not have a history of sales or if sales volume is not sufficient, the Company relies on prices set by its pricing committees or applicable marketing department adjusted for expected discounts. Variable Consideration The Company exercises judgment in estimating variable consideration, which includes volume discounts, sales rebates, product returns and other adjustments. These amounts are recorded as a reduction to revenue and classified as a current liability. The Company bases its estimates for volume discounts and sales rebates on historical information to the extent it is reasonable to be used as a predictive tool of expected future rebates. To the extent the transaction price includes variable consideration, the Company applies judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. The Company evaluates constraints based on its historical and projected experience with similar customer contracts. The Company’s contracts for the sale of capital equipment and related components, and assays and tests typically do not provide the right to return product, however, its contracts for the sale of its GYN Surgical and Interventional Breast Solutions surgical handpieces provide for a right of return for a limited period of time. In general, estimates of variable consideration and constraints are not material to the Company’s financial statements. Remaining Performance Obligations As of March 29, 2025, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately $901.1 million. These remaining performance obligations primarily relate to support and maintenance obligations and extended warranty in the Company’s Breast Health and Skeletal Health reportable segments. The Company expects to recognize approximately 27% of this amount as revenue in fiscal 2025, 37% in fiscal 2026, 20% in fiscal 2027, 10% in fiscal 2028, and 6% thereafter. As permitted, the Company does not include remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above. Contract Assets and Liabilities The Company discloses accounts receivable separately in the Consolidated Balance Sheets at their net realizable value. Contract assets primarily relate to the Company’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial. Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much lesser extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily relates to support and maintenance contracts and extended warranty obligations within the Company’s Breast Health and Skeletal Health reportable segments. Contract liabilities are classified as other current liabilities and other long-term liabilities in the Consolidated Balance Sheets. The Company recognized revenue of $39.8 million and $109.8 million in the three and six months ended March 29, 2025, respectively, that was included in the contract liability at September 28, 2024. The Company recognized $37.1 million and $101.6 million in the three and six months ended March 30, 2024, respectively, that was included in the contract liability at September 30, 2023. Practical Expedients The Company applies a practical expedient to expense costs to obtain a contract with a customer as incurred when the amortization period would have been one year or less. These costs solely comprise sales commissions and typically the commissions are incurred at the time of shipment of product and upon billings for support and maintenance contracts.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4 + Details
Name: | us-gaap_RevenueRecognitionPolicyTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration